The tyrosine kinase inhibitor nintedanib enhances the efficacy of 90 Y-labeled B5209B radioimmunotherapy targeting ROBO1 without increased toxicity in small-cell lung cancer xenograft mice.
Journal Information
Full Title: Nucl Med Commun
Abbreviation: Nucl Med Commun
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Nuclear Medicine
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Conflicts of interest There are no conflicts of interest."
"This study was supported in part by JSPS KAKENHI under grant numbers JP16K19809, JP18K15335, and 20K08148. This study was supported in part by JSPS KAKENHI under grant numbers JP16K19809, JP18K15335, and 20K08148."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025